Latest Roche Stories
Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives.
IPSWICH, Mass., July 13 /PRNewswire/ -- New England Biolabs (NEB) has expanded its line of reagents for sample preparation with the introduction of NEBNext(TM) Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium(TM) and GS Junior(TM) instruments.
WALTHAM, Mass., July 1 /PRNewswire/ -- X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
YORKTOWN HEIGHTS, N.Y. and BRANFORD, Conn., July 1 /PRNewswire-FirstCall/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced today an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently.
NUTLEY, N.J., June 16 /PRNewswire/ -- Armed with a clear focus on helping orphaned children locally as well as thousands of miles away, more than 900 local Roche employees are participating today in the Seventh Annual Roche Children's Walk to raise funds to support children infected and affected by HIV/AIDS in New Jersey and Africa.
PRINCETON, N.J., June 9, /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated.
INDIANAPOLIS, June 1 /PRNewswire/ -- Roche, makers of ACCU-CHEKÂ® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C.
LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ -- - Trial to Study Patients with Colorectal and Ovarian Cancer ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers.
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
PRINCETON, N.J., May 4 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), in response to certain inaccuracies in an article published by PharmaWire on May 3, 2010 about its development program for treatment of hepatitis C virus (HCV) in collaboration with Hoffmann-La Roche Inc. and F.